Lung NETs and Their Treatment


Cancers that arise in the lung are mostly of the type known as NSCLC (non-small cell lung carcinoma). A much smaller proportion of lung tumors arise from neuroendocrine cells in the lungs. These cells (which are also found in most other organs) secrete a variety of hormones that are necessary for normal organ function, as well as for healing after injury or infection. Like other lung cells, neuroendocrine cells may transform to become cancers. Lung cancers that arise from neuroendocrine cells are called pulmonary neuroendocrine tumors (NETs), or lung NETs. Continue reading…


Adjuvant Chemotherapy Associated with Shorter Survival in LCNEC

“Patients who underwent adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinomas demonstrated poorer 3-year survival than those who did not undergo adjuvant treatment, according to study results presented at the American Association for Thoracic Surgery Annual Meeting.

“ ‘We did not see any particular subset of patients who may benefit from this treatment,’ researcher Pier Luigi Filosso, MD, of the University of Torino in Italy, said during a presentation.

“Filosso and colleagues conducted a retrospective cohort study to determine the impact of adjuvant chemotherapy in patients with resected large cell neuroendocrine carcinomas (LCNEC). The analysis included 400 patients with LCNEC who underwent surgery between 1992 and 2014 at one of 14 institutions worldwide.

“Researchers used the Kaplan-Meier method to estimate OS after resection. Propensity score for the likelihood of receipt of adjuvant chemotherapy was estimated based on patient age, gender, prior malignancy, ECOG performance status, TNM stage and year of surgery.”